Price
$1.34
Decreased by -2.90%
Dollar Volume
2.76 M
ADR%
15.42
Earnings Report Date (estimate)
Nov 10, 22 (N/A)
Market Cap.
6.40 M
Shares Float
3.59 M
Shares Outstanding
4.78 M
Beta
-0.62
Price / Earnings
-4.32
BPR
4.46
20D Range
1.09 2.35
50D Range
1.06 2.35
200D Range
1.06 16.65
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 15, 21 -0.75
Increased by +16.67%
-0.75
Aug 16, 21 -0.90
Increased by +45.45%
-0.90
May 17, 21 -0.90
Increased by +25.00%
-0.90
Mar 31, 21 -0.90
Increased by +81.82%
-0.90
Nov 4, 20 -0.90
Increased by +57.14%
-1.50
Increased by +40.00%
Aug 14, 20 -1.65
Increased by +74.42%
-1.50
Decreased by -10.00%
May 11, 20 -1.20
Increased by +90.24%
-2.55
Increased by +52.94%
Mar 30, 20 -4.95
Increased by +10.81%
-4.20
Decreased by -17.86%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-662.00 K
Increased by +76.51%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-604.00 K
Increased by +36.35%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-2.86 M
Decreased by -186.67%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-3.73 M
Decreased by -72.43 M%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-2.82 M
Decreased by -174.12%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-949.00 K
Increased by +49.74%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-998.00 K
Increased by +19.65%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-5.15
Increased by +100.00%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.